tisagenlecleucel + ibrutinib

C<strong class="">tisagenlecleucel + ibrutinib</strong> is an experimental combination therapy used in clinical trials to treat relapsed or refractory B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Tisagenlecleucel is an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy that works by genetically modifying a patient's own T cells to recognize and eliminate CD19-expressing B cells, including malignant ones[6][8]. Ibrutinib is a first-in-class oral small molecule Bruton’s tyrosine kinase (BTK) inhibitor that interferes with B-cell receptor signaling, inhibiting malignant B-cell proliferation, survival, adhesion, and trafficking[2][4]. Preclinical and early clinical studies have suggested that combining tisagenlecleucel with ibrutinib may enhance anti-tumor immunity and improve response rates by synergistically targeting B-cell malignancy through both direct cytotoxicity (CAR-T targeting CD19) and disruption of pro-survival BCR signaling (ibrutinib inhibition of BTK)[3][5][7].